These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 18060703)

  • 21. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anatomy-based inverse planning dose optimization in HDR prostate implant: a toxicity study.
    Mahmoudieh A; Tremblay C; Beaulieu L; Lachance B; Harel F; Lessard E; Pouliot J; Vigneault E
    Radiother Oncol; 2005 Jun; 75(3):318-24. PubMed ID: 16086913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of influence of age on acute and chronic radiotherapy toxicity in treatment of prostate cancer.
    Jani AB; Parikh SD; Vijayakumar S; Gratzle J
    Urology; 2005 Jun; 65(6):1157-62. PubMed ID: 15913725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer.
    Gardner BG; Zietman AL; Shipley WU; Skowronski UE; McManus P
    J Urol; 2002 Jan; 167(1):123-6. PubMed ID: 11743288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intensity-modulated radiotherapy as primary treatment for prostate cancer: acute toxicity in 114 patients.
    De Meerleer G; Vakaet L; Meersschout S; Villeirs G; Verbaeys A; Oosterlinck W; De Neve W
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):777-87. PubMed ID: 15465194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.
    Kalakota K; Liauw SL
    Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
    Koper PC; Jansen P; van Putten W; van Os M; Wijnmaalen AJ; Lebesque JV; Levendag PC
    Radiother Oncol; 2004 Oct; 73(1):1-9. PubMed ID: 15465140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute toxicity in 50 patients with prostate cancer treated with conformal radiation therapy].
    Nasr E; Merhej S; Nehme Nasr D; Fares G
    J Med Liban; 2001; 49(6):325-8. PubMed ID: 12744634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N; Azria D; Thézenas S; Barbier N; Fenoglietto P; Delard R; Hay MH; Dubois JB
    Cancer Radiother; 2004 Apr; 8(2):59-69. PubMed ID: 15063872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization.
    Woel R; Beard C; Chen MH; Hurwitz M; Loffredo M; McMahon E; Ching J; Lopes L; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):392-6. PubMed ID: 15890580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
    Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
    Madsen BL; Hsi RA; Pham HT; Fowler JF; Esagui L; Corman J
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1099-105. PubMed ID: 17336216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.
    Nath SK; Sandhu AP; Rose BS; Simpson DR; Nobiensky PD; Wang JZ; Millard F; Kane CJ; Parsons JK; Mundt AJ
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):435-41. PubMed ID: 19939580
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?
    Chen MJ; Weltman E; Hanriot RM; Luz FP; Cecílio PJ; da Cruz JC; Moreira FR; Santos AS; Martins LC; Nadalin W
    Radiat Oncol; 2007 Jan; 2():6. PubMed ID: 17224072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between acute and late toxicity in 973 prostate cancer patients treated with three-dimensional conformal external beam radiotherapy.
    Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Serafini F; Cambria R; Vavassori A; Cattani F; Garibaldi C; Gherardi F; Ferrari A; Rocco B; Scardino E; de Cobelli O; Orecchia R
    Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):26-34. PubMed ID: 20133085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined brachytherapy with external beam radiotherapy for localized prostate cancer: reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy.
    Zelefsky MJ; Nedelka MA; Arican ZL; Yamada Y; Cohen GN; Shippy AM; Park JJ; Zaider M
    Brachytherapy; 2008; 7(1):1-6. PubMed ID: 18299108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer.
    Koper PC; Heemsbergen WD; Hoogeman MS; Jansen PP; Hart GA; Wijnmaalen AJ; van Os M; Boersma LJ; Lebesque JV; Levendag P
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1072-82. PubMed ID: 15001247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.